Ivana Micallef
Overview
Explore the profile of Ivana Micallef including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
459
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Desai S, Laplant B, Macon W, King R, Wang Y, Inwards D, et al.
Blood Cancer J
. 2021 Sep;
11(9):160.
PMID: 34564694
Diffuse large B-cell lymphoma (DLBCL), either concurrent with or transformed from follicular lymphoma (FL) is often excluded from clinical trials. Lenalidomide has response rates of 45% in relapsed transformed DLBCL....
12.
Khurana A, Hathcock M, Habermann T, Saleh A, Gandhi S, Truong T, et al.
Am J Hematol
. 2021 Jul;
96(10):E386-E389.
PMID: 34260759
No abstract available.
13.
Zanwar S, Abeykoon J, Durot E, King R, Perez Burbano G, Kumar S, et al.
Am J Hematol
. 2019 Dec;
95(3):274-281.
PMID: 31814157
Histological transformation in Waldenström macroglobulinemia (WM) is an uncommon complication, with limited data, particularly regarding the impact of MYD88 mutation on transformation. We examined risk factors and outcomes associated with...
14.
Farooq U, Maurer M, Thompson C, Thanarajasingam G, Inwards D, Micallef I, et al.
Br J Haematol
. 2017 Jun;
179(1):50-60.
PMID: 28653407
This study aimed to describe the patterns of care and outcomes of diffuse large B cell lymphoma (DLBCL) after failure of front line anthracycline-based immunochemotherapy (IC). Patients with newly diagnosed...
15.
Ding W, LaPlant B, Call T, Parikh S, Leis J, He R, et al.
Blood
. 2017 Apr;
129(26):3419-3427.
PMID: 28424162
Chronic lymphocytic leukemia (CLL) patients progressed early on ibrutinib often develop Richter transformation (RT) with a short survival of about 4 months. Preclinical studies suggest that programmed death 1 (PD-1)...
16.
DSouza A, Lacy M, Gertz M, Kumar S, Buadi F, Hayman S, et al.
Blood
. 2012 May;
120(1):56-62.
PMID: 22611150
The POEMS syndrome (polyradiculoneuropathy, organomegaly, multiple endocrinopathies, monoclonal protein, skin changes) is a rare disease associated with a plasma cell dyscrasia. Patients with disseminated POEMS can be treated with high-dose...
17.
Jiang L, Malik S, Litzow M, Gastineau D, Micallef I, Roy V, et al.
Transfusion
. 2011 Aug;
52(3):542-8.
PMID: 21827503
Background: Marrow damage from chemo- and radiation therapies has been suggested to affect quality and quantity of hematopoietic stem cell (HSC) products. We tested the hypothesis that CD34+ cells (HSCs)...
18.
Stiff P, Micallef I, Nademanee A, Stadtmauer E, Maziarz R, Bolwell B, et al.
Biol Blood Marrow Transplant
. 2010 Dec;
17(8):1146-53.
PMID: 21126595
Autologous hematopoietic stem cell transplantation (ASCT) is an established treatment for patients with hematologic malignancies, yet the impact of transplanted CD34(+) cell dose on clinical outcomes is unresolved. We conducted...
19.
Winter J, Inwards D, Spies S, Wiseman G, Patton D, Erwin W, et al.
J Clin Oncol
. 2009 Mar;
27(10):1653-9.
PMID: 19255322
Purpose: To determine the maximum-tolerated radiation-absorbed dose (RAD) to critical organs delivered by yttrium-90 ((90)Y) ibritumomab tiuxetan in combination with high-dose carmustine, etoposide, cytarabine, and melphalan (BEAM) chemotherapy with autologous...
20.
Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Weisdorf D, Territo M, et al.
Biol Blood Marrow Transplant
. 2009 Jan;
15(2):249-56.
PMID: 19167685
We investigated the efficacy and toxicity of combining granulocyte-colony stimulating factor (G-CSF) at standard doses with plerixafor, a CXCR4 inhibitor, to mobilize stem cells in patients with non-Hodgkin's lymphoma (NHL)...